Noocil, 100 mg/ml 10 ml 10 pcs

Citicoline

Indications

Acute period of ischemic stroke (cerebral infarction) (as part of complex therapy).
Recovery period of ischemic and hemorrhagic stroke.
Traumatic brain injury (TBI): acute (as part of complex therapy) and recovery period.
Cognitive and behavioral disorders in degenerative and vascular diseases of the brain.

Pharmacological effect

Pharmacotherapeutic group:

nootropic agent.

ATX code: N06BX06

Pharmacological properties

Pharmacodynamics

Citicoline, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a wide spectrum of action – it promotes the restoration of damaged cell membranes, inhibits the action of phospholipases, prevents the excessive formation of free radicals, and also prevents cell death by affecting the mechanisms of apoptosis. In the acute period of stroke, citicoline reduces the volume of damage to the brain substance and improves cholinergic transmission.

In case of traumatic brain injury, it reduces the duration of post-traumatic coma and the severity of neurological symptoms, in addition, helps reduce the duration of the recovery period. In chronic cerebral hypoxia, citicoline is effective in the treatment of cognitive disorders,

such as memory impairment, lack of initiative, difficulties in performing everyday activities and self-care. Increases the level of attention and consciousness, and also reduces the manifestation of amnesia.

Citicoline is used in the treatment of sensory and motor neurological disorders of degenerative and vascular etiology.

Pharmacokinetics

Suction

Citicoline is well absorbed when taken orally. Absorption after oral administration is almost complete, and bioavailability is approximately the same as after intravenous administration.

Metabolism

The drug is metabolized in the intestines and liver with the formation of choline and cytidine. After administration, the concentration of choline in the blood plasma increases significantly.

Distribution

Citicoline is widely distributed in brain structures, with the rapid introduction of the choline fraction into structural phospholipids and the cytidine fraction into cytidine nucleotides and nucleic acids. Citicoline penetrates the brain and is actively integrated into cellular, cytoplasmic and mitochondrial membranes, taking part in the construction of the phospholipid fraction.

Removal

Only 15% of the administered dose of citicoline is excreted from the human body: less than 3% by the kidneys and through the intestines and about 12% by exhaled CO2.

The excretion of citicoline in urine can be divided into 2 phases: a first phase, lasting about 36 hours, during which the rate of excretion decreases rapidly, and a second phase, during which the rate of excretion decreases much more slowly. The same thing is observed in exhaled CO2 – the rate of elimination decreases rapidly after about 15 hours, and then decreases much more slowly.

Special instructions

In the cold, a small amount of crystals may form due to temporary partial crystallization of the preservative. With further storage under recommended conditions, the crystals dissolve within several months. The presence of crystals does not affect the quality of the drug.

Impact on the ability to drive vehicles and machinery

During the treatment period, care should be taken when performing potentially hazardous activities that require special attention and speed of psychomotor reactions (driving a car and other vehicles, working with moving mechanisms, working as a dispatcher and operator, etc.).

Active ingredient

Citicoline

Composition

Per 1 ml:

Active ingredient: citicoline sodium – 104.50 mg, equivalent to citicoline – 100.00 mg.

Excipients: methyl parahydroxybenzoate – 1.45 mg; propyl parahydroxybenzoate – 0.25 mg; potassium sorbate – 3.00 mg; sodium saccharinate – 0.20 mg; sorbitol – 200.00 mg; glycerol – 50.00 mg; sodium citrate – 6.00 mg; strawberry flavoring – 0.41 mg; citric acid – 1.00 mg; purified water – up to 1 ml.

Pregnancy

There are no sufficient data on the use of citicoline in pregnant women. Although animal studies have not revealed any negative effects, during pregnancy the drug is prescribed only in cases where the expected benefit to the mother outweighs the potential risk to the fetus.

When prescribing the drug during lactation, women should stop breastfeeding, since there is no data on the excretion of citicoline in human milk, and the risk to the child cannot be completely excluded.

Contraindications

hypersensitivity to any of the components of the drug,
patients with severe vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system),
children under 18 years of age (due to the lack of sufficient clinical data).

Side Effects

Adverse events (AEs) are grouped by systems and organs in accordance with the MedDRA dictionary and the WHO classification of the incidence of AEs: very often (≥1/10); often (≥1/100 to <1/10); uncommon (≥1/1000 to <1/100); rare (≥1/10000 to <1/1000); very rare (< 1/10000); frequency unknown (frequency cannot be determined from available data).From the nervous system: very rarely – headache, dizziness, reactions from the parasympathetic system, tremor, numbness in paralyzed limbs.From the mental side: very rarely – hallucinations, insomnia, agitation.Vascular disorders: very rarely – arterial hypotension, arterial hypertension.Disorders of the respiratory system, chest and mediastinal organs: very rarely – shortness of breath.From the digestive system: very rarely – loss of appetite, nausea, vomiting, diarrhea.From the skin and subcutaneous tissues: very rarely – hyperemia, purpura, anaphylactic shock, urticaria, rash, itching.General disorders and disorders at the injection site: very rarely – chills, feeling of heat, swelling.Disorders of the liver and biliary tract: very rarely – changes in the activity of liver enzymes.If any of the side effects indicated in the instructions get worse, or any other side effects not listed in the instructions are noticed, you should inform your doctor.

Interaction

Citicoline enhances the effects of levodopa.

Should not be used concomitantly with medicinal products containing meclofenoxate

Overdose

Given the low toxicity of the drug, cases of overdose have not been described. In case of accidental overdose, treatment is symptomatic.

Storage conditions

At a temperature not exceeding 25 °C.

Keep out of the reach of children!

Shelf life

3 years. Do not use after expiration date.

Manufacturer

Ozon, Russia